CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
LY2140023 Reference form +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01591330
NCT01591330Phase 1Completed
CompareCT.gov

A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects

Denovo Biopharma LLC·interventional·Posted May 4, 2012·Updated Sep 21, 2021

In Brief

A Phase 1 clinical trial evaluating LY2140023 Reference form, LY2140023 Test-Low, and 2 other interventions for Healthy Volunteers. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The study will evaluate the effect of different particle size of LY2140023. The study involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a washout period of at least 3 days between doses. This study will last approximately 60 days not including screening. Screening is required within 30 days prior to study entry.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 4, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.2 years ago

Interventions

LY2140023 Reference formdrug

80-mg tablet administered orally

LY2140023 Test-Lowdrug

80-mg tablet administered orally

LY2140023 Test-Mediumdrug

80-mg tablet administered orally

LY2140023 Test-Highdrug

80-mg tablet administered orally